Advertisement

Topics

Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

14:00 EDT 23 Sep 2016 | Biotech 365

HUDDINGE, Sweden–(BUSINESS WIRE)–Regulatory News: Medivir AB (STO:MVIRB) today announced that updated interim data from a phase IIa study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen), were presented on September 23rd at the European Association … Continue reading

Cet article Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients est apparu en premier sur Biotech 365.

Original Article: Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

NEXT ARTICLE

More From BioPortfolio on "Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients"

Quick Search
Advertisement